reviewed april 2026|next review october 2026|88 physicians psi has verified|397064 published studies
Decorin
Decorin is a naturally occurring (the body's own) small leucine-rich proteoglycan that acts as a natural myostatin antagonist in skeletal muscle while also regulating collagen fibril assembly, inhibiting TGF-beta signaling in fibrosis, and demonstrating anti-tumor properties.
Evidence landscape: 397064 published studies
397,064 published items (broad proteoglycan/ECM query). 38 human studies and 143 animal studies.
- 38 Human
- 143 Animal
- 19 Reviews
- 396864 Other research
Not FDA-approved. Not in clinical development. No clinical trials are registered for decorin as a therapeutic. Decorin is a naturally occurring (the body's own) extracellular matrix protein produced throughout connective tissues.
Not available as a therapeutic. Recombinant decorin is available for research purposes only. Small peptide fragments marketed as decorin may not replicate the biological activity of the intact 40 kDa proteoglycan.
Decorin is a 40 kDa small leucine-rich proteoglycan (SLRP) that 'decorates' collagen fibrils (hence the name). It binds and neutralizes both myostatin and TGF-beta, acts as a natural myostatin antagonist, and inhibits multiple receptor tyrosine kinases (EGFR, Met, VEGFR2). Exercise increases decorin expression in skeletal muscle.
PSI Assessment
The body already produces a molecule that blocks myostatin, organizes collagen, fights fibrosis, and inhibits tumor growth. Decorin is a small leucine-rich proteoglycan found throughout the extracellular matrix that 'decorates' collagen fibrils (hence the name). In 2014, Kanzleiter et al. published in Cell Metabolism that exercise increases decorin expression in skeletal muscle, and that decorin directly binds and neutralizes myostatin. This made decorin one of the first identified exercise-induced myostatin antagonists. The anti-fibrotic properties (TGF-beta neutralization) and anti-tumor properties (EGFR, Met, VEGFR2 inhibition) add dimensions that most muscle-focused peptides lack. Decorin knockout mice develop spontaneous tumors, confirming the tumor-suppressive function. The challenge is therapeutic translation: decorin is a large proteoglycan (40 kDa), not a small injectable peptide, and delivery of intact decorin to target tissues at therapeutic concentrations has not been solved.
The body already produces a myostatin-blocking molecule. Exercise increases its expression. Also regulates collagen assembly and has anti-tumor properties.
Decorin is a 40 kDa small leucine-rich proteoglycan (SLRP) with a single glycosaminoglycan chain (chondroitin sulfate or dermatan sulfate). It binds collagen fibrils, regulating fibril diameter and spacing in the extracellular matrix. It binds and sequesters TGF-beta isoforms, functioning as a natural anti-fibrotic agent. It binds and neutralizes myostatin, functioning as a natural myostatin antagonist in skeletal muscle. And it inhibits receptor tyrosine kinases including EGFR (triggering receptor internalization and degradation), Met (hepatocyte growth factor receptor), and VEGFR2 (vascular endothelial growth factor receptor), producing documented anti-tumor effects. Exercise increases decorin expression in muscle, providing a molecular link between physical activity and myostatin regulation. Decorin knockout mice develop spontaneous intestinal and hepatic tumors, confirming the tumor-suppressive role.
What the evidence supports
Decorin binds and neutralizes myostatin with high affinity, functioning as a naturally occurring (the body's own) myostatin antagonist. Exercise increases decorin expression in skeletal muscle. Decorin regulates collagen fibril diameter and spacing in the extracellular matrix. Anti-fibrotic effects through TGF-beta neutralization are documented across organ systems. Anti-tumor properties through receptor tyrosine kinase inhibition (EGFR, Met, VEGFR2) are published.
What is not yet established
Whether exogenous decorin administration enhances the body's natural myostatin inhibition beyond what exercise achieves. Therapeutic delivery and dosing for anti-fibrotic or anti-tumor applications. Whether decorin-based therapies can be developed for muscle wasting. Clinical trial data for any therapeutic indication.
Research Evidence
The findings below cover the multiple biological roles of decorin and the translational challenge of therapeutic delivery.
Evidence by condition
Evidence dimensions available for each condition Decorin has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Myostatin Regulation | ||||
| Anti-Fibrotic Research | ||||
| Collagen Biology | ||||
| Cancer Research |
Decorin binds and neutralizes myostatin with high affinity, functioning as a naturally occurring (the body's own) myostatin antagonist. Exercise increases decorin expression in skeletal muscle. This was published in Cell Metabolism (Kanzleiter et al., 2014).
This positioned decorin as an exercise-induced myostatin inhibitor, distinct from pharmaceutical approaches (bimagrumab, ACE-031) that target the same pathway through engineered molecules.
38 Human|143 Animal|19 Reviews
View all 397064 indexed studiesHow Decorin Works
Decorin is a 40 kDa small leucine-rich proteoglycan (SLRP) with a single glycosaminoglycan chain. It is found throughout the extracellular matrix of connective tissues and is expressed by fibroblasts, myocytes, and other cell types.
Decorin acts like a quality controller for tissue repair. When the body heals a wound, it produces collagen. Decorin organizes those collagen fibers into proper patterns rather than disorganized scar tissue. It also acts as a sponge for TGF-beta, a protein that drives excessive scarring when overactive.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Decorin is a 40 kDa small leucine-rich proteoglycan (SLRP) with a single glycosaminoglycan chain. It binds TGF-beta isoforms, sequestering them in the extracellular matrix. It also binds EGFR, triggering receptor internalization. Decorin promotes p21WAF1 expression and modulates Met receptor signaling.
What is Decorin being studied for?
Researchers are studying Decorin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Decorin overall. This means a compound can have human studies for one condition but only animal data for another.
Myostatin Regulation
·Animal StudiesDecorin directly binds and neutralizes myostatin in skeletal muscle. Exercise increases decorin expression. This represents a naturally occurring (the body's own) myostatin inhibition pathway.
Limitations: Whether exogenous decorin administration enhances myostatin inhibition beyond what exercise achieves is unknown. Therapeutic delivery of a 40 kDa proteoglycan to muscle tissue has not been solved.
Anti-Fibrotic Research
·Animal StudiesDecorin sequesters TGF-beta in the extracellular matrix, preventing the excessive fibrotic signaling that drives scar formation. Anti-fibrotic effects are documented in cardiac, pulmonary, and renal animal models.
Limitations: No human clinical trials for anti-fibrotic applications. Delivery of intact decorin to fibrotic tissues at therapeutic concentrations is unsolved.
Collagen Biology
·Human TrialsDecorin regulates collagen fibril diameter and spacing in the extracellular matrix. The 'decoration' of collagen fibrils by decorin is its namesake function and is well-characterized across decades of research.
Limitations: The collagen regulation role is fundamental biology, not a therapeutic indication. Whether modulating decorin levels can improve wound healing or tissue quality in humans is unproven.
Cancer Research
·Animal StudiesDecorin inhibits EGFR (triggering receptor internalization), Met, and VEGFR2, producing anti-tumor effects. Decorin knockout mice develop spontaneous tumors, confirming the tumor-suppressive function.
Limitations: Anti-tumor effects are from animal models (preclinical). Therapeutic delivery for cancer applications has not been developed.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. No clinical trials registered for decorin as a therapeutic agent.
Availability: Not available as a therapeutic. Recombinant decorin is available for research only. Small peptide fragments sold commercially may not replicate intact proteoglycan activity.
Class context: Decorin is a naturally occurring (the body's own) extracellular matrix protein. No safety concerns from normal physiology. The therapeutic challenge is delivery of a large 40 kDa molecule, not toxicity.
Decorin is naturally occurring (the body's own) in connective tissues with no safety concerns from normal physiology. Therapeutic development faces challenges related to molecule size rather than toxicity. The 40 kDa proteoglycan cannot be taken orally or easily delivered to target tissues at therapeutic concentrations.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Decorin discussion.
Comparison and Related Research
Decorin connects to the myostatin pathway, exercise biology, and anti-fibrotic research spaces.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identified decorin as an exercise-induced myokine released from contracting muscle. The study demonstrated that decorin directly binds and inhibits myostatin, a key negative regulator of muscle growth, providing a mechanistic explanation for how exercise-released decorin promotes muscle hypertrophy.Kanzleiter T et al., 2014 in Biochem Biophys Res Commun. View on PubMed
- 2.Comprehensive review of decorin's established role in extracellular matrix biology. Decorin is a small leucine-rich proteoglycan that binds to collagen fibrils and regulates their assembly, playing a critical role in tissue architecture and wound healing. This matrix function is distinct from its later-discovered role as an exercise-released myokine.Reed CC & Iozzo RV, 2002 in Glycoconj J. View on PubMed
- 3.Animal study demonstrating that decorin protein core inhibited tumor growth in vivo by blocking epidermal growth factor receptor (EGFR) signaling and triggering programmed cell death. These anti-tumor properties represent a separate line of research from the muscle and matrix biology of decorin.Seidler DG et al., 2006 in J Biol Chem. View on PubMed
- 4.Mapped the specific region of decorin that interacts with TGF-beta, showing that this binding site is distinct from the collagen-binding domain. This dual binding capacity allows decorin to simultaneously regulate both collagen fibril organization and TGF-beta signaling, which influences inflammation, fibrosis, and tissue repair.Schonherr E et al., 1998 in Arch Biochem Biophys. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.